- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Avalon GloboCare (ALBT) Surges Over 36% After Hours: Here's What Is Happening | 2 | Benzinga.com | ||
| Mi | Avalon GloboCare Corp. - S-1, General form for registration of securities | - | SEC Filings | ||
| 01.04. | Aktionäre von Avalon GloboCare geben grünes Licht für möglichen Reverse Split der Aktie | - | Investing.com Deutsch | ||
| 01.04. | Avalon GloboCare Corp. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Avalon GloboCare beauftragt AWS-Partner mit Ausbau seiner KI-Videoplattform | 1 | Investing.com Deutsch | ||
| 31.03. | Avalon GloboCare Corp.: Avalon Quantum AI Announces Strategic Collaboration with Caylent, an Amazon Web Services Premier Tier Partner, to Advance its Catch-Up Product into a Fully Autonomous Agentic AI Video Platform | 3 | GlobeNewswire (USA) | ||
| 28.02. | Avalon GloboCare closes $3.25 million private placement | 11 | Investing.com | ||
| 27.02. | Avalon GloboCare Corp.: Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| AVALON GLOBOCARE Aktie jetzt für 0€ handeln | |||||
| 27.02. | Avalon GloboCare: Aktie stürzt nach verwässernder Privatplatzierung ab | 3 | Investing.com Deutsch | ||
| 27.02. | Avalon GloboCare announces $9.75M private placement | 5 | Seeking Alpha | ||
| 27.02. | Avalon GloboCare prices $3.25M private placement at $0.51/share | 2 | Investing.com | ||
| 27.02. | Avalon GloboCare Corp.: Avalon GloboCare Announces up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 26.02. | Avalon GloboCare joins AMD AI developer program | 7 | Investing.com | ||
| 26.02. | Avalon GloboCare Corp.: Avalon GloboCare's Subsidiary Accepted into AMD AI Developer Program to Advance Next-Generation Media Infrastructure | 14 | GlobeNewswire (USA) | ||
| 26.02. | EXCLUSIVE: Avalon GloboCare Partners With AMD To Supercharge AI | 15 | Benzinga.com | ||
| 25.02. | Avalon GloboCare schließt Finanzierungsvereinbarung über 233.910 $ ab und gibt Wechsel im Verwaltungsrat bekannt | 3 | Investing.com Deutsch | ||
| 25.02. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.02. | Avalon GloboCare Corp.: Avalon GloboCare Eliminates Majority of Debentures Through $2.6 Million Conversion, Strengthening Balance Sheet, Reduces Overhang | 91 | GlobeNewswire (Europe) | Conversion Improves Capital Structure, and Reinforces Nasdaq Compliance, Enhancing Shareholder Value Company Believes That Substantially All of the Converted Shares Have Been Sold FREEHOLD, N.J.,... ► Artikel lesen | |
| 02.02. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,530 | +0,09 % | Aufgepasst! Riesiges Marktpotenzial im größten Teilbereich der Pharmabranche nutzen: mit Innovator Vidac Pharma, Platzhirsch Bayer oder Turnaround-Kandidat Evotec? | Die Onkologie ist der strategisch wichtigste Wachstumsmarkt der Pharmaindustrie und gleichzeitig einer der entscheidenden Hebel zur Verbesserung der globalen Gesundheit. Aktuell erkranken weltweit rund... ► Artikel lesen | |
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Where Will Viking Therapeutics Stock Be in 10 Years? | ||
| DEFENCE THERAPEUTICS | 0,350 | +5,42 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,420 | +2,94 % | Strategische Weichenstellung im Exosomenmarkt | ||
| ABIVAX | 106,40 | -0,75 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| IDEXX LABORATORIES | 487,50 | -1,93 % | IDEXX Laboratories, Inc.: IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma | Helping clinicians investigate sooner and plan next steps with confidence IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the availability... ► Artikel lesen | |
| IBIO | 1,841 | -0,32 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 55,36 | 0,00 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,154 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,928 | +2,20 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| CYBIN | 4,450 | 0,00 % | Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer | Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,012 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CAPRICOR | 26,140 | -1,73 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen |
Das Unternehmen AVALON GLOBOCARE CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,021 (-4,37 %) liegt der Kurs bei 0,459 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVALON GLOBOCARE CORP finden Sie auf Wallstreet Online.